Original Source(s)
Related Content
First IL-17A biologic approved for polymyalgia rheumatica
Sustained remission reached 40.5% with secukinumab vs 20.5% with placebo at 52 weeks, alongside lower steroid exposure.
by Mouj Hijazi
November 17, 2026
-
2 min
B antigen transfusions may raise allergy risk
Patients with blood type O showed a stronger reaction signal in US regions with high alpha-gal syndrome prevalence.
August 27, 2026
-
4 min
FDA approves pritelivir for refractory HSV lesions
In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.
by Teraya Smith
October 9, 2026
-
2 min